Science Advances | 南模生物助力揭示骨质疏松和骨折愈合治疗新靶点
目前，全世界有超过2亿人罹患骨质疏松症，50岁以上人群中，骨量丢失导致老年人骨折风险及死亡率快速上升，每5名男性或3名女性中就有一人可能遭遇骨质疏松骨折。破骨细胞和成骨细胞共同维持骨代谢的平衡。抗骨吸收药物单纯抑制破骨细胞功能，阻碍了正常骨改建，对已经发生的严重骨质疏松效果不佳，存在影响骨折愈合的风险。近年来，促骨形成的靶点和药物越来越受到科研人员的重视。
2020年11月19日，海军军医大学苏佳灿/陈晓/陈啸飞研究团队在Science Advances 杂志在线发表了题为“Targeting Actin-Bundling Protein L-Plastin as an Anabolic Therapyfor Bone Loss”的研究成果，该研究发现L-Plastin可以作为治疗骨质疏松和促进骨折愈合的潜在靶点。
南模生物为该研究构建了L-Plastin敲除小鼠模型。
图1 L-Plastin敲除小鼠骨量显著上升
南模生物作为一家专注于模式生物领域的高新技术企业，始终以编辑基因、解码生命为己任，专业从事遗传修饰动物模型的研发、饲养繁育和分析检测。致力于为全球高校、科研院所、医院、制药企业提供全面、便捷、专业的模式生物技术服务和模型资源。
你也可能感兴趣
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
